Global burden of latent multidrug-resistant tuberculosis : trends and estimates based on mathematical modelling by Knight, G.M. et al.
This is a repository copy of Global burden of latent multidrug-resistant tuberculosis : trends
and estimates based on mathematical modelling.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/148461/
Version: Published Version
Article:
Knight, G.M., McQuaid, C.F., Dodd, P.J. orcid.org/0000-0001-5825-9347 et al. (1 more 
author) (2019) Global burden of latent multidrug-resistant tuberculosis : trends and 
estimates based on mathematical modelling. The Lancet Infectious Diseases. ISSN 
1473-3099 
https://doi.org/10.1016/s1473-3099(19)30307-x
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
www.thelancet.com/infection   Published online July 4, 2019   http://dx.doi.org/10.1016/S1473-3099(19)30307-X 1
Articles
Global burden of latent multidrug-resistant tuberculosis: 
trends and estimates based on mathematical modelling
Gwenan M Knight, C Finn McQuaid, Peter J Dodd*, Rein M G J Houben*
Summary
Background To end the global tuberculosis epidemic, latent tuberculosis infection needs to be addressed. All standard 
treatments for latent tuberculosis contain drugs to which multidrug-resistant (MDR) Mycobacterium tuberculosis is 
resistant. We aimed to estimate the global burden of multidrug-resistant latent tuberculosis infection to 
inform tuberculosis elimination policy.
Methods By fitting a flexible statistical model to tuberculosis drug resistance surveillance and survey data collated by 
WHO, we estimated national trends in the proportion of new tuberculosis cases that were caused by MDR strains. We 
used these data as a proxy for the proportion of new infections caused by MDR M tuberculosis and multiplied trends 
in annual risk of infection from previous estimates of the burden of latent tuberculosis to generate trends in the 
annual risk of infection with MDR M tuberculosis. These estimates were used in a cohort model to estimate changes 
in the global and national prevalence of latent infection with MDR M tuberculosis. We also estimated recent infection 
levels (ie, in 2013 and 2014) and made predictions for the future burden of MDR tuberculosis in 2035 and 2050.
Findings 19·1 million (95% uncertainty interval [UI] 16·4 million–21·7 million) people were latently infected with MDR 
tuberculosis in 2014—a global prevalence of 0·3% (95% UI 0·2–0·3). MDR strains accounted for 1·2% (95% UI 1·0–1·4) 
of the total latent tuberculosis burden overall, but for 2·9% (95% UI 2·6–3·1) of the burden among children younger 
than 15 years (risk ratio for those younger than 15 years vs those aged 15 years or older 2·65 [95% UI 2·11–3·25]). Recent 
latent infection with MDR M tuberculosis meant that 1·9 million (95% UI 1·7 million–2·3 million) people globally were 
at high risk of active MDR tuberculosis in 2015.
Interpretation We estimate that three in every 1000 people globally carry latent MDR tuberculosis infection, and 
prevalence is around ten times higher among those younger than 15 years. If current trends continue, the proportion 
of latent tuberculosis caused by MDR strains will increase, which will pose serious challenges for management of 
latent tuberculosis—a cornerstone of tuberculosis elimination strategies.
Funding UK Medical Research Council, Bill & Melinda Gates Foundation, and European Research Council.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Tuberculosis is the infectious disease responsible for the 
most deaths worldwide. The complex natural history of 
Mycobacterium tuberculosis means that, for ultimate 
disease control, people with latent infections need to be 
targeted.1,2 Latent tuberculosis infection is deined as “a 
state of persistent immune response to stimulation by 
M tuberculosis antigens with no evidence of clinically 
manifest active tuberculosis”.3 As much as 23% of 
the world’s population could have latent tuberculosis 
infection, and, even if transmission stopped in 2014, 
reactivation disease would overwhelm the 2035 End TB 
targets.4 Thus, understanding and targeting of latent 
tuberculosis is a priority for elimination,2 as recognised 
by the 2018 UN High-Level Meeting on Tuberculosis.5
Antimicrobial resistance is an increasingly serious 
threat to global public health.6 Multidrug-resistant (MDR) 
strains of M tuberculosis, which are resistant to both 
key irst-line tuberculosis drugs (ie, rifampicin and 
isoniazid), are responsible for approximately a quarter of 
all deaths caused by antimicrobial-resistant infections.7 In 
2017, MDR tuberculosis contributed to as estimated 
14% of tuberculosis deaths globally.8 In patients with 
MDR tuberculosis, appropriate diagnosis is infrequent, 
treatment success is low, and treatment regimens are 
unacceptably long (ie, >18 months). MDR tuberculosis 
already accounts for a disproportionally large proportion 
of the inancial burden for tuberculosis control pro- 
grammes.8 Prevention of an increase in the incidence of 
MDR tuberculosis from a growing reservoir of latent 
MDR infection (ie, latent tuberculosis caused by MDR 
M tuberculosis strains) is therefore crucial for the success 
of any tuberculosis control programme.
Worryingly, MDR M tuberculosis strains are resistant to 
all recommended therapies for people with latent infection 
who are not known contacts of a person with active MDR 
tuberculosis disease.3 The priority population for testing 
and preventive therapy for latent infection is household 
contacts of tuberculosis patients,9 who are likely to be 
infected by their household member.10 However, in settings 
where the incidence of new infections is high, infection 
also frequently occurs outside the home.10 Because of such 
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external transmission11 and the low proportion of people 
with active MDR tuberculosis disease detected (<30%),8 a 
substantial proportion of people with latent MDR 
infections will not have had recognised contacts with active 
MDR tuberculosis, and standard preventive therapy could 
be less efective. All diagnostics for latent tuberculosis 
infection rely on measurement of immune responses,9 
and cannot establish the strain or susceptibility of 
M tuberculosis. Hence, estimation of the prevalence of 
latent MDR tuberculosis infection can help to inform 
estimates of the eicacy of standard therapy for latent 
infection. These estimates can also help to guide the use of 
tailored preventive treatment for contacts of patients with 
active MDR tuberculosis disease3,12 and clarify the speciic 
demand for new regimens (that include levoloxacin and 
delamanid) being tested.13–15
Additionally, as the overall incidence of tuberculosis 
and the annual risk of infection decrease, fewer people 
will be infected with latent tuberculosis (both drug-
susceptible and MDR strains), which is thought to partly 
protect against reinfection with M tuberculosis.16–18 If the 
tuberculosis epidemic becomes increasingly driven by 
transmission of MDR strains, the presence of an existing 
protective primary drug-susceptible latent infection 
becomes less likely, which could further facilitate an 
increasing burden of MDR tuberculosis disease 
in younger generations.19 Thus, a decrease in the total 
prevalence of latent tuberculosis infection could result 
in MDR strains accounting for an increased proportion 
of latent infections overall.
No direct data for the prevalence of latent 
MDR tuberculosis are available, because infecting 
M tuberculosis strains cannot be isolated, and thus 
cannot be tested for resistance. Hence, a modelling 
approach is the only way to estimate this metric of the 
tuberculosis burden. We developed a new mathematical 
model that follows cohorts over time and applies 
historical annual risk of infection data to estimate 
trends in the risk of new infections with MDR 
M tuberculosis and the global prevalence of latent MDR 
tuberculosis infection.
Methods
Data sources
In this mathematical modelling study, we created a model 
that combined historical annual risks of infection 
(estimated in a previous study4) with trends in the 
proportion of new tuberculosis Cases that are MDR as a 
proxy for the proportion of the annual risk of infection 
that is MDR.20 This approach enabled us to estimate 
trends in the risk of MDR M tuberculosis infection, and 
hence the proportion of each cohort with latent 
tuberculosis infection that carried MDR M tuberculosis, 
and in turn to generate global estimates of the prevalence 
of latent MDR tuberculosis. As a starting point, we used 
Houben and Dodd’s estimates4 of historical annual risks 
Research in context
Evidence before this study
We searched PubMed with the terms “(TB OR tubercul*) 
AND (global OR latent OR LTBI) AND burden AND model* 
AND (“resist*” OR “multidrug*” OR “MDR-” OR drug-resistant)” 
for articles published in English up to Nov 1, 2018. We identified 
68 articles, including one by Houben and Dodd (our source for 
historical annual risks of infection), who estimated total global 
latent tuberculosis infections and the number of recent latent 
tuberculosis infections in each country that were resistant to 
isoniazid. Mehra and colleagues’ mathematical modelling study 
showed that the burden of multidrug-resistant (MDR) latent 
tuberculosis infection in China was increasing, by contrast with 
the burden of drug-susceptible disease. Dodd and colleagues 
used a constant annual risk of infection to estimate the burden 
of MDR latent tuberculosis in children in a modelling study. 
By reviewing the reference lists of the results of our search, 
we identified a mathematical modelling study by Mills and 
colleagues exploring isoniazid preventive therapy, which 
showed that the burden of latent isoniazid-resistant infection 
was increasing under all scenarios (with and without preventive 
therapy) in Lesotho. However, we identified no studies in which 
the global burden of MDR latent tuberculosis infection was 
estimated in all age groups or in which historical trends in drug 
resistance were accounted for in estimations of the burden of 
MDR latent tuberculosis infection.
Added value of this study
In this study, we provide the first estimates of the global burden 
of latent MDR tuberculosis infection in all age groups across 
multiple settings. In the absence of empirical estimates, we have 
provided a robust modelling approach that accounts for the 
uncertainty in data for MDR tuberculosis to give 138 country-level 
estimates for the burden of latent MDR infection. We showed 
that the prevalence of latent MDR tuberculosis is higher in people 
younger than 15 years than in those aged 15 years or older. We 
estimate that, in 2015, approximately 2 million people were at 
increased risk of MDR tuberculosis disease after recent infection 
(ie, infection in 2013 or 2014).
Implications of all the available evidence
Targeting latent tuberculosis infection is essential for 
tuberculosis elimination, but standard preventive treatment 
regimens are probably ineffective against latent MDR strains. 
The estimates for the proportion of latent tuberculosis 
infections caused by MDR strains, and associated variations by 
setting and age we have provided should help to inform clinical 
decision making about regional preventive treatment regimens 
for latent MDR tuberculosis. Our estimates signal a worrying 
trend of an increasing burden of latent MDR tuberculosis in 
children younger than 15 years.
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of infection with latent tuberculosis globally. They 
combined tuberculin skin test surveys with prevalence 
data and a revised Styblo rule to generate the annual risk 
of infection with any M tuberculosis strain for 
168 countries.4 A previous systematic review showed that 
the prevalence of MDR tuberculosis in children and 
treatment-naive adults with tuberculosis was a relection 
of the local transmission of MDR disease.20 Hence, we 
used the proportion of new tuberculosis cases (survey or 
surveillance data) reported to WHO’s Drug Resistance 
Surveillance (DRS) project that were MDR as a proxy for 
the proportion of the annual risk of infection with 
M tuberculosis that was caused by MDR strains. 
138 countries had available data from both Houben and 
Dodd’s study4 and the DRS project. These countries 
accounted for 93% of all incident tuberculosis cases and 
96% of the MDR tuberculosis burden in 2016, and 
included 28 of the 30 countries with a high burden of 
MDR tuberculosis according to WHO.8 The two high-
burden countries not included (Angola and DR Congo) 
had no DRS data available; each contributed less than 
1·5% of the estimated global incident MDR tuberculosis 
burden in 2016.8 Full details of country selection are in the 
appendix (pp 3–4).
Model generation
We itted curves to the data points in the WHO DRS data 
to generate trends for the country level proportions of 
new tuberculosis cases that MDR strains accounted for. 
Posteriors of potential its provided 200 samples. These 
samples were multiplied by the trend estimates for the 
total annual risk of infection with M tuberculosis4 to give 
the annual risk of infection with either drug-susceptible 
or MDR M tuberculosis strains.
Curves were itted through a lexible statistical model 
using a Bayesian Markov chain Monte Carlo approach 
in the RStan package in R.21 Our model allows for 
increases, stabilisation, and also subsequent decreases 
in the proportion of new cases that are MDR over time. 
In the absence of extensive timeseries data, the model 
was itted with informative priors, which relected three 
data-based assumptions about the trend characteristics 
of multidrug resistance, to constrain the potential 
pattern of increases in the prevalence of MDR 
tuberculosis disease. First, we assumed that the 
appearance of detectable levels of MDR tuberculosis in 
any country before 1970 was very unlikely (appendix 
p 5). To capture this time constraint, the model itted for 
each country a time when the proportion of new 
tuberculosis cases that were MDR was assumed to be 
measurable. The prior for this parameter was normally 
distributed with a mean of 1985 and a 95% range 
between 1970 and 2000, which matched a previous 
modelling study’s assumption that transmissible MDR 
strains of M tuberculosis strains emerged 20–60 years 
before 2013.22 Second, the rate of increase in the 
proportion of new cases that were MDR was governed 
by two parameters (appendix pp 6 –10) that were scaled 
to prevent too rapid an increase while still capturing the 
wide range of MDR prevalences (including some very 
low rates of increase). Third, we ensured that our model 
did not allow for a peak and crash in the proportion of 
new tuberculosis cases that were MDR. The details for 
the choice of priors and plots of the trends generated by 
these assumptions are in the appendix (pp 6–10, 19–27).
Model outcomes
We inputted estimates of the annual risk of infection for 
both drug-susceptible and MDR M tuberculosis into a new 
cohort model, and tracked the proportion of individuals 
by age infected with drug-susceptible or MDR strains 
(appendix pp 14–16) from 1934 to 2014. The initial 
conditions were calculated assuming a constant annual 
risk of infection before 1934, and we assumed that there 
was no MDR tuberculosis before 1960. Estimates of the 
burden of latent tuberculosis infection in 2014 are 
presented, because 2014 was the inal timepoint in the 
annual risk of infection trends.4 On the basis of previous 
work,16 our model assumed that 79% of people with latent 
tuberculosis infection were protected against reinfection.
We included all available WHO DRS data in the itting 
process—ie, for trends in the proportion of new 
tuberculosis cases that is MDR, we used WHO data 
up to 2018.
Speciically, the burden we aimed to characterise was 
the number of individuals with a persistent immune 
response to stimulation by M tuberculosis antigens 
without evidence of clinically manifested active disease.3 
We report the resistance status (ie, drug susceptible or 
MDR) of the last infecting strain, taking into account 
protection against reinfection, ignoring dual infections, 
and, in the absence of a quantitative alternative, assuming 
lifelong infection.
We used model outputs to estimate the population 
infected with MDR M tuberculosis in 2013 or 2014 
(ie, the most recent 2 years for which annual risk of 
infection trends4 were available), who would be at a 
higher risk of progressing to active MDR tuberculosis 
in 2015 than those infected earlier. We calculated the 
risk ratio (RR) of people younger than 15 years having 
latent MDR tuberculosis (conditional on being latently 
infected) compared with those aged 15 years or 
older. We chose 15 years as the age cutof to match 
previous age-segregated estimates of latent tuberculosis 
infection and because it is a standard cutof in the 
natural history of tuberculosis, as relected in 
WHO data.8
To estimate the contribution of latent MDR tuber- 
culosis infections in 2015 to disease burden in 2035 and 
2050, we assumed no transmission of M tuberculosis 
after 2014. We used UN Population Division demo- 
graphic projections23 to estimate the burden of latent 
MDR tuberculosis in 2035 and 2050 and the incidence 
of active MDR disease assuming a 0·03% per year 
See Online for appendix
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remote activation rate, and explored this value in a 
sensitivity analysis.24 We compared our results to the 
overall WHO End TB targets of less than ten 
tuberculosis cases per 100 000 population by 2035, and 
the Stop TB target of less than one case per million 
population by 2050.1
To compare how well our estimates of the burden of 
latent MDR tuberculosis were informed by resistance 
data, we used the cohort model to establish the proportion 
of latent infection in 2014 in each country  in each 5-year 
time block in the past. The sum of all 5-year time blocks 
for which any WHO DRS data were available gave the 
data coverage value (appendix pp 28–32). This metric 
combined the contribution of a speciic period to the 
burden of latent MDR tuberculosis with whether data 
were present during that time to compare the availability 
of data for MDR infection by setting. The higher the 
value, the greater the overlap between contribution of a 
period to the burden of latent MDR infection and data 
availability.
Sensitivity analysis
The itness costs associated with the appearance of 
resistance within M tuberculosis strains are debated.25,26 
We did a sensitivity analysis in which we applied a 
40% itness cost25 to the protection from reinfection 
(ie, a reduction from 79% to 47%), and separately to the 
rate of reactivation (ie, a reduction from 0·03% per year 
to 0·018% per year), in people with latent MDR 
tuberculosis. We also did a sensitivity analysis on trend 
shape, in which we allowed for more lexible dynamics 
in the annual risk of infection with MDR tuberculosis 
in a subset of countries with suicient data and a 
potential peak and crash in the proportion of all cases 
of disease that were caused by MDR strains 
(appendix pp 11 –14).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
Figure 1: Proportion of new cases of tuberculosis disease accounted for by MDR tuberculosis in the nine countries in the WHO South-East Asia region included 
in our model
The blue lines represent the median proportion from 200 model fits to WHO data (the red datapoints; error bars show 95% CIs). The shaded regions represent the 
95% uncertainty intervals. Although we estimated the burden of latent MDR tuberculosis in 2014 (hence the cutoff in this figure) the model trend was fitted to all 
WHO Drug Resistance Surveillance data. MDR=multidrug resistant.
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all the data in the study and had inal responsibility for 
the decision to submit for publication.
Results
Estimates of the proportion of new cases of tuberculosis 
that MDR tuberculosis accounted for were provided by 
model its for all 138 countries, and closely matched 
WHO data (appendix pp 19–27). Examples of model its 
for countries in the WHO South-East Asia region are 
shown in igure 1, which shows the substantial 
uncertainty associated with the lack of data before 1990 
and the rising trend in the proportion of new cases that 
are caused by MDR tuberculosis across all countries.
We estimated a global prevalence of latent MDR 
tuberculosis infection in 2014 of 0·3% (95% uncertainty 
interval [UI] 0·2–0·3; table 1), representing 19·1 million 
(95% UI 16·4 million–21·7 million) people (table 2). 
1·2% (95% UI 1·0–1·4) of the global burden of latent 
tuberculosis infection was due to MDR strains. Our 
estimates of the overall prevalence of latent tuberculosis 
infection (ie, both drug-susceptible and MDR infections; 
table 1) matched those from previous modelling,4 
validating the cohort model approach that we used.
Our model’s outputs relected data showing that the 
proportion of tuberculosis disease caused by MDR 
strains is increasing, and suggested that the prevalence 
of latent MDR tuberculosis infection has increased 
substantially across all six WHO regions since 1990 
(igure 2). Our estimates of the prevalence of latent MDR 
tuberculosis infection varied geographically, with the 
lowest prevalence in the WHO Americas region 
(0·1% [95% UI 0·0–0·1]) and the highest in the WHO 
European region (2·8% [1·6–3·9]; igure 2; table 1). Most 
countries included in our model had a prevalence of 
latent MDR tuberculosis of less than 1%, but prevalence 
in some countries in eastern Europe and central Asia 
was higher than 1·5% (igure 3; appendix p 17). Among 
the 30 countries with the largest burden of MDR 
tuberculosis, the proportion of latent tuberculosis 
caused by MDR was highest in Kazakhstan (17·5% 
[95% UI 6·5–22·9]). China (approximately 6 million), 
India (4 million), and Russia (1·8 million) had the 
highest absolute numbers of people with latent MDR 
tuberculosis (appendix p 17).
In children younger than 15 years, the global proportion 
of latent tuberculosis that was caused by MDR strains 
was 2·9% (95% UI 2·6–3·1)—more than double that in 
the overall population (table 1). In the WHO European 
region, 14·1% (95% UI 13·1–15·2) of latent tuberculosis 
in children younger than 15 years was caused by MDR 
strains, compared with 2·8% (1·6–3·9) in the total 
population (table 1). In most WHO regions there was a 
peak in latent MDR tuberculosis infections between ages 
20 years and 35 years (igure 4). The RR for a latent 
infection being caused by an MDR strain in people 
younger than 15 years versus those aged 15 years or older 
was 2·65 (95% UI 2·11–3·25).
The number of people infected with latent MDR 
tuberculosis infection in 2013 and 2014 was estimated to 
be 1·9 million (95% UI 1·7 million–2·3 million)—0·03% 
(95% UI 0·02–0·03) of the global population in 
2014. We estimated that 0·6 million (95% UI 
0·6 million–0·8 million) children younger than 15 years 
had been infected with latent MDR tuberculosis in 2013 
and 2014, who were therefore at high risk of progression 
to MDR tuberculosis disease in 2015.
Assuming no ongoing transmission from 2015, we 
projected 14 million (95% UI 12 million–16 million) cases 
of latent MDR tuberculosis surviving until 2035, 
decreasing to 11 million (95% UI 10 million–12 million) 
by 2050 (appendix). Incidence of MDR disease from this 
latent pool would be 0·5 (95% UI 0·4–0·5) per million 
people per year in 2035 and 0·3 (0·3–0·4) per million 
people per year in 2050. These estimates do not exceed 
the 2035 WHO End TB or 2050 Stop TB targets.1
The mean of the metric for data coverage across all 
countries and model its was 0·56 (range 0–1). 14 countries 
had median metric values of 1, suggesting that data were 
available within all contributing periods (appendix pp 
29–30). Four countries (Bhutan, Djibouti, Sudan, and 
Togo) had no metric values because data were available 
only after 2014 (appendix pp 29–30). The best data 
coverage for the 30 countries with the highest burden 
of MDR tuberculosis was in Russia, Thailand, and 
Prevalence (95% uncertainty interval) Proportion (95% uncertainty interval)
Drug-susceptible 
latent tuberculosis
Multidrug-resistant 
latent tuberculosis
Latent tuberculosis 
that is multidrug 
resistant
Latent tuberculosis 
that is multidrug 
resistant in people 
younger than 15 years
African 22·1% (20·1–25·5) 0·23% (0·19–0·29) 1·0% (0·8–1·3) 2·3% (1·9–2·7)
Americas 10·6% (7·3–19·0) 0·05% (0·04–0·06) 0·5% (0·3–0·8) 3·3% (2·8–4·1)
South-East Asia 30·7% (27·7–34·5) 0·31% (0·23–0·41) 1·0% (0·7–1·3) 2·2% (1·9–2·6)
Eastern 
Mediterranean
16·4% (13·5–20·9) 0·14% (0·08–0·24) 0·9% (0·5–1·5) 2·9% (1·9–3·8)
Western Pacific 26·8% (17·8–39·2) 0·36% (0·26–0·49) 1·3% (0·7–2·2) 3·7% (3·3–4·1)
European 13·5% (9·9–19·8) 0·38% (0·32–0·44) 2·8% (1·6–3·9) 14·1% (13·1–15·2)
Global 22·9% (20·1–26·1) 0·28% (0·24–0·31) 1·2% (1·0–1·4) 2·9% (2·6–3·1)
Table 1: Prevalence of latent tuberculosis infection, 2014, by WHO region
Drug-susceptible latent 
tuberculosis (thousands)
Multidrug-resistant latent 
tuberculosis (thousands)
African 155 000 (141 000–179 000) 1590 (1310–2010)
Americas 102 000 (70 700–183 000) 510 (418–624)
South-East Asia 584 000 (527 000–656 000) 5810 (4410–7750)
Eastern Mediterranean 96 000 (78 900–122 000) 837 (481–1410)
Western Pacific 493 000 (326 000–720 000) 6620 (4840–9000)
European 122 000 (90 100–180 000) 3440 (2920–3990)
Global 1 580 000 (1 380 000–1 800 000) 19 100 (16 400–21 700)
Data are n (95% uncertainty interval).
Table 2: Number of people with latent tuberculosis infection, 2014, by WHO region
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Uzbekistan (median metric values 0·87–0·99); Zimbabwe 
was the only of these countries with a median metric 
value less than 0·25 (appendix pp 29–30). The top four 
countries in terms of absolute numbers of people infected 
with latent MDR tuberculosis (appendix p 18)—ie, China, 
India, Indonesia, and Russia—had median metric values 
higher than 0·5.
In sensitivity analyses, a 40% reduction in the protective 
efect of latent MDR tuberculosis against reinfection 
resulted in a less than 1% diference to all our results for 
the prevalence of latent MDR tuberculosis (appendix 
p 33). The RR for latent MDR tuberculosis infect by age 
decreased slightly to 2·47 (95% UI 2·03–2·97). A 
40% itness cost afecting progression from latent MDR 
disease to active MDR disease (reactivation) reduced the 
incidence of active disease to 0·29 (95% UI 0·25–0·32) 
per million per year in 2035 and to 0·20 (0·18–0·23) per 
million per year in 2050. Allowing for more lexible 
dynamics resulted in a pre-1995 peak (ie, before data 
were available) in the proportion of new tuberculosis 
cases that MDR strains account for in the three countries 
included (ie, China, India, and the USA). This peak 
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Figure 2: Prevalence of latent multidrug-resistant tuberculosis infection, by WHO region
The red line represents the median from 200 model fits. The shaded region represents the 95% uncertainty interval.
Figure 3: Estimated worldwide prevalence of latent multidrug-resistant tuberculosis infection
Countries with no data are shown in grey. Equivalent maps for 2035 and 2050 estimates are in the appendix.
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increased estimates of the overall prevalence of latent 
MDR tuberculosis infection but had little efect on 
estimates in people younger than 15 years (appendix 
pp 36–38).
Discussion
We estimated that, in 2014, the global prevalence of latent 
MDR tuberculosis infection was 0·3% (95% UI 0·2–0·3). 
Prevalence varied substantially by WHO region and age 
group, but was increasing in all regions. The proportion 
of latent infections with MDR tuberculosis strains was 
1·2% (95% UI 1·0–1·4) in the overall population, but 
more than double that in children younger than 15 years. 
We estimated that if all transmission stopped in 2015, the 
number of new cases caused by reactivation of latent 
MDR tuberculosis infection would not exceed the one 
per million targets for tuberculosis elimination by 2050, 
but would contribute approximately a third of the target.1
Our analysis suggests that prevalence of latent MDR 
tuberculosis peaks in people aged 20–35 years , relecting 
the combination of lower prevalence of latent infections 
in younger age groups because of lower cumulative 
exposure time and an increase in the proportion of 
infections caused by MDR strains beginning in the early 
1990s. A high burden of latent MDR tuberculosis in 
children was estimated previously, but the model on 
which this estimate was based assumed a constant annual 
risk of infection over time and did not consider other age 
groups.27 We showed that children had double the risk of 
having a latent tuberculosis infection that was caused by a 
MDR strain compared with adults, which is worrying in 
view of the higher frequency of progression to active 
disease and lower probability of appropriate diagnosis or 
treatment for MDR tuberculosis in children compared 
with adults.28 In terms of the future burden of MDR 
tuberculosis, these children also represent a long-
persistent reservoir for MDR disease in the absence 
of substantial and efective rollout of new preventive 
therapy programmes for latent tuberculosis. This burden 
is driven by the increasing proportion of the annual risk 
of infection that is accounted for by MDR tuberculosis as 
the overall annual risk of infection decreases globally. 
Hence, children are more likely to be infected with MDR 
M tuberculosis than the current generation of adults were. 
Indeed, the current generation of adults are partly 
protected by the higher prevalence of latent drug-
susceptible tuberculosis infection,16–18 which makes 
them less likely to have latent MDR tuberculosis infection. 
The public health implications of these indings are that, 
independently of contact with people with active MDR 
tuberculosis, latent tuberculosis infections in children 
should be considered more likely to have been caused by 
an MDR strain.
The WHO regions with the highest prevalence of 
latent MDR tuberculosis infection (ie, the European and 
Western Paciic regions) in 2014 in our model were the 
regions with the highest proportion of new cases of 
tuberculosis caused by MDR strains in the WHO 2018 
Figure 4: Prevalence of latent multidrug-resistant tuberculosis infection in each age group, by WHO region
Error bars show 95% uncertainty intervals. The prevalence of latent infection with drug-susceptible tuberculosis is shown in the appendix.
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Global TB report.8 These estimates, alongside country-
level estimates, should help to guide preventive therapy 
in some settings: a high proportion of latent tuberculosis 
infections being caused by MDR M tuberculosis in high 
incidence settings could suggest that standard preventive 
therapy for latent infections should be given with even 
more caution to household contacts and that possible 
second-line therapies, such as those being trialed,13–15 
should be considered.
Our estimates showed that the prevalence of latent 
MDR tuberculosis is increasing in all regions, as has 
been estimated previously for China29 and for latent 
isoniazid-resistant infection in Lesotho,30 despite WHO 
estimates suggesting that the incidence of new cases 
of MDR tuberculosis has stabilised. Our aim was to 
characterise historical patterns of change in the annual 
risk of infection with MDR strains to inform the burden 
of latent MDR tuberculosis rather than to establish 
trends in the incidence of MDR disease.
We have created a generalisable approach that com- 
bines historical country-level data with generally 
informative priors on emergence of MDR tuberculosis 
disease to estimate the global prevalence of latent MDR 
tuberculosis infection. We used informative priors to 
capture the timings of isoniazid and rifampicin use and 
limited rates of increase to better support the data 
available. A strength of our approach is the inclusion of a 
range of trajectories for the proportion of new cases of 
tuberculosis that are caused by MDR strains. Our model 
could also track infection by age, which showed the 
increasing burden of latent MDR disease in younger age 
groups. We also included sensitivity analyses around the 
efect of MDR disease on protection from reinfection and 
the rate of reactivation, which showed that the former 
had little efect on our results whereas the latter reduced 
predicted incidence of active MDR tuberculosis by 
approximately 40% (in line with the assumed parameter 
reduction). This inding highlights the importance of 
establishing the rate of reactivation for forecast analysis.
However, our analysis also had several limitations. 
First, we relied on historical trends for the proportion of 
new cases of tuberculosis that was due to MDR strains, 
even though data for before 1990 are scarce. By setting 
relatively informative priors (eg, the emergence of MDR 
strains before 1970 is very unlikely) and allowing for both 
quadratic and linear curves, we think that we have 
explored a reasonable range of potential MDR trends and 
relect this in our wide uncertainty ranges, but this 
analysis was fundamentally limited by the amount and 
precision of data. We explored an even wider range of 
potential trends in a sensitivity analysis for a small set of 
countries with a high burden of MDR disease, for which 
data suggested a potential peak in the annual risk of 
infection with MDR tuberculosis before data were 
available, by itting more lexible spline models. Although 
this peak afected our results, it assumed that 
transmission of MDR tuberculosis rose rapidly from 
1970 onwards and pushed the limits of the available data. 
However, the overall prevalence of latent MDR 
tuberculosis infection is clearly sensitive to data and 
assumptions for pre-2000 trends, and future work could 
include past trend determination, especially for China 
(possibly through phylogenetic analysis), because 
alternative potential past trends contributed most to the 
estimated change in the prevalence of latent MDR 
tuberculosis. Our data availability metric shows that 
most of the 30 countries with the highest prevalence of 
MDR infection had good data availability (ie, median 
metric values higher than 0·5). New drug resistance 
surveys or improved surveillance are needed to estimate 
recent prevalence of MDR tuberculosis, which could 
then be used to update our estimates of the prevalence of 
latent MDR tuberculosis. When countries had both 
survey and surveillance data available, we did not treat 
the data diferently (eg, to account for potential under-
reporting in surveillance).
A second limitation was the homogeneity assumed in 
the model in terms of contact patterns, strain diferences, 
reactivation rates, spatial variation, and population 
characteristics. By not including diferences in mixing 
patterns by age, we might have missed some age variation: 
age-assortative mixing, combined with changing disease 
presentation,31 could result in further diferences between 
children and adults. In terms of strain variation, reduced 
reactivation rates for MDR tuberculosis had a substantial 
efect on the future incidence of MDR disease in our 
model, suggesting that strain variation diferences in 
reactivation rates could drive diferences in MDR incidence 
globally. For example, future work could estimate variance 
in the prevalence of latent MDR tuberculosis by HIV 
status, which could have con- sequences for assumed 
itness costs to resistance and hence could be associated 
with a greater prevalence of latent MDR tuberculosis 
infection in HIV-positive populations. Similarly, we 
modelled, and averaged surveillance and survey data, at 
the national level, which for some settings, such as Russia, 
might not be appropriate.
We also assumed lifelong infection, despite the 
likelihood that self-cure is possible after infection with 
M tuberculosis.19 Most estimates of the prevalence of latent 
tuberculosis infection are based on tuberculin skin tests. 
Some people with positive tuberculin skin test results 
could have cleared their M tuberculosis infection, 
suggesting that the reservoir of true infection for 
reactivation is smaller than the estimated prevalence of 
latent infection (which is deined through persistent 
immune response).32 We also present data for recent 
infections (ie, in 2013 and 2014), which would have caused 
most cases of active MDR tuberculosis disease in 2015. 
We accounted for our potential overestimation of the 
population carrying MDR M tuberculosis in the estimated 
future number of people with reactivation MDR disease 
that arises from the reservoir of latent MDR infection The 
implications for global elimination targets are likely to be 
Articles
www.thelancet.com/infection   Published online July 4, 2019   http://dx.doi.org/10.1016/S1473-3099(19)30307-X 9
robust. We also modelled only multidrug resistance and 
not all rifampicin resistance, because historical data were 
available only for the former.
A further complexity that we did not explore was mixed 
infection, because the dynamics of reactivation and 
mixed strain disease, although important, are not fully 
understood.33 Latent infection was assumed to be caused 
by the last successfully infecting strain (eg, either MDR 
or drug-susceptible M tuberculosis, taking into account 
protection against reinfection). However, in view of the 
relatively low annual risk of infection  since the rise of 
MDR prevalence from around 1985, compared with the 
decades before, potential mixed infections probably 
account for a low proportion of all cases of latent MDR 
tuberculosis, and are unlikely to afect the total number 
of cases with latent MDR or drug-susceptible infection.
Furthermore, in our main analysis we used a single-
study estimate for the level of protection against 
reinfection progression conferred by latent infection,16 
despite the availability of other estimates.17,18 This estimate 
used in our model captured potential risk reductions in 
infection and progressive tuberculosis dependent on 
latent tuberculosis status, which currently cannot be 
separated. We explored the efect of this parameter by 
lowering the protection against reinfection conferred by 
latent MDR tuberculosis infection in our sensitivity 
analysis, which showed a less than 1% change to the 
prevalence of latent MDR infection. We did not include a 
sensitivity analysis for all latent tuberculosis infections 
because the efect on MDR disease, and the efect in 
previous work4 of reducing protection from the mean 79% 
that we used to 50% for all latent infections, were so small. 
The only efect noted in previous work,4 which was 
relected in the slightly reduced risk ratio for latent MDR 
tuberculosis by age in our sensitivity analysis, was on the 
age distribution of recent infections, with an increased 
proportion of infections in older age groups.
The broader public health implications of this work are 
that evidence for the eicacy of preventive therapies for 
people potentially infected with latent MDR tuberculosis 
needs to be strengthened and the recommendations 
possibly made context speciic. Our estimates also 
provide some idea of the value of a diagnostic test to 
diferentiate between the resistance status of latent 
tuberculosis strains. In terms of future modelling work, 
the rate and proportion of self-clearance of latent 
tuberculosis infection should be quantiied to better 
estimate the size of the reactivation reservoir. For future 
transmission, the efect of any itness costs conferred by 
resistance carriage in M tubercolosis on natural history 
progression should be explored, and trends in the annual 
risk of infection with MDR M tuberculosis should be 
further established.
Our estimates suggest that one in every 83 individuals 
with latent tuberculosis is infected with a MDR strain of 
M tuberculosis, which means that nearly three in every 
1000 people globally carry latent MDR tuberculosis. 
However, among children younger than 15 years, one in 
every 34 people with latent tuberculosis is infected with 
MDR strains, and this number will be even higher among 
close contacts of people with active MDR disease. We also 
found that the prevalence of latent MDR tuberculosis 
infection is increasing in all WHO regions. Under current 
trends, the proportion of latent disease caused by MDR 
strains is only going to increase, with serious implications 
for control of latent tuberculosis infections—a cornerstone 
of tuberculosis elimination strategies.
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